Your session is about to expire
← Back to Search
Examining a Digital Health Approach for Advancing Schizophrenia Illness Self-management and Provider Engagement
N/A
Waitlist Available
Research Sponsored by Centre for Addiction and Mental Health
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 27 months.
Awards & highlights
No Placebo-Only Group
Summary
This trial tests a new app called App4Independence (A4i) designed to help people with schizophrenia manage their symptoms and stay on their treatment plans. The app provides reminders, coping tips, and ways to connect with peers and healthcare providers. The goal is to see if this app can improve treatment engagement and reduce hospital readmissions for people with schizophrenia.
Eligible Conditions
- Schizophrenia
- Modeling Psychosis
- Psychosis
- Schizoaffective Disorder
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 27 months.
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~27 months.
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Incidence of Treatment-Emergent Adverse Events
Objective App Use
Recruitment
+1 moreSecondary study objectives
App Strengths and Limitations
Appointment Attendence
Clinical Alliance
+6 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
2Treatment groups
Experimental Treatment
Active Control
Group I: A4i InterventionExperimental Treatment1 Intervention
App4Independence (A4i)
Experimental: A4i Intervention App4Independence (A4i) The study intervention is the digital health platform A4i. A4i operates on the individual's own phone with or without data.
Specific A4i functionality includes:
* Addressing social isolation and cognitive challenges through personalized prompts, scheduling of activities, and connections to a range of resources.
* Fostering illness self-management through evidence-informed content.
* A peer-peer engagement platform that facilitates strategy/tip sharing between users (anonymous and moderated).
* Daily wellness and goal attainment check-ins.
* An ambient sound detector with an oscilloscope-type indicator that assists individuals with auditory hallucinations separate hallucinations from real sounds.
* Passively collected data on phone use as a proxy for sleep.
* A provider dashboard. Both control and experimental condition participants will be receiving standard outpatient care (TAU).
Group II: Treatment As UsualActive Control1 Intervention
Treatment as usual participants will be recieving outpatient mental health care through the standard supports (most typically, case management and psychiatric support) that are available in a large, Canadian, urban centre.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
A4i Intervention
2021
N/A
~90
Find a Location
Who is running the clinical trial?
Centre for Addiction and Mental HealthLead Sponsor
372 Previous Clinical Trials
82,745 Total Patients Enrolled
59 Trials studying Schizophrenia
4,221 Patients Enrolled for Schizophrenia